Tumor Biology

, Volume 35, Issue 3, pp 2095–2102

Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis

  • Shiyao He
  • Yu-hong Tang
  • Guobin Zhao
  • Xiaolong Yang
  • Dehou Wang
  • Ye Zhang
Research Article

Abstract

Pioglitazone is widely used for glycemic control in patients with type 2 diabetes mellitus, but evidence regarding the association between pioglitazone and bladder cancer risk is confusing. A systematic search of databases was carried out, and other relevant papers were also identified. Then, the analyses were conducted according to the PRISMA and MOOSE guidelines. After quality assessment, nine datasets from 10 available studies were included on the basis of inclusion criteria. The incidence of bladder cancer among pioglitazone ever users and never users, pooled from four cohort and one randomized studies, were 84.51 and 66.68 per 100,000 person-years, respectively. Nine studies representing 2,596,856 diabetic patients were recognized as eligible for overall study; the result suggested an increased risk of bladder cancer in patients exposed to pioglitazone. A persistent significance was detected after being adjusted by age, gender, and use of other diabetes medications. Subgroup analyses indicated that the significantly increased incidence of bladder cancer was found in men, but not in women. Additionally, the analyses addressing increasing exposure to pioglitazone observed a dose–response relation between exclusive ever use of pioglitazone and bladder cancer in terms of cumulative duration of use and cumulative dosage. With some limitations, our results suggest an increased risk of bladder cancer in diabetic patients using pioglitazone, especially for men with long-term and high-dose exposure. Additional studies are needed to provide more precise evidences to support our results.

Keywords

Pioglitazone Bladder cancer Diabetes Meta-analysis 

Supplementary material

13277_2013_1278_MOESM1_ESM.pdf (155 kb)
ESM 1(PDF 155 kb)

References

  1. 1.
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Kao CH, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, et al. Benzodiazepine use possibly increases cancer risk: a population-based retrospective cohort study in Taiwan. J Clin Psychiatry. 2012;73:e555–60.PubMedCrossRefGoogle Scholar
  3. 3.
    Food and Drug Administration. FDA drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm (accessed Oct 1, 2010)
  4. 4.
    Zhang H, Zhu S, Chen J, Tang Y, Hu H, Mohan V, et al. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care. 2012;35:1388–93.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–89.PubMedCrossRefGoogle Scholar
  6. 6.
    Dormandy J, Bhattacharya M, van Troostenburg DBA. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32:187–202.PubMedCrossRefGoogle Scholar
  7. 7.
    Li W, Macdonald TM, Mackenzie IS. Pioglitazone and bladder cancer. A propensity score matched cohort study. Br J Clin Pharmacol. 2012. doi:10.1111/j.1365-2125.2012.04325.x.Google Scholar
  8. 8.
    Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35:278–80.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953–62.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55:1462–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case–control study. BMJ. 2012;344:e3645.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34:1369–71.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CJ, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916–22.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Questions and answers on the review of pioglitazone-containing medicines (Actos, Glustin, Competact, Glubrava and Tandemact). European Medicines Agency. 2011. www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2011/07/WC500109179.pdf. Accessed Oct 2012.
  15. 15.
    Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012;184(12):E675–83.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Phillips B, Ball C, Sackett D, et al. Levels of evidence and grades of recommendation. Oxford Centre for Evidence-based Medicine Web site. http://www.cebm.net/index.aspx?o=1025. Accessed Oct 2012.
  19. 19.
    Zhu S, Zhang H, Tang Y, Liu P, Wang J. DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case–control studies. Mol Biol Rep. 2012;39:4429–37.PubMedCrossRefGoogle Scholar
  20. 20.
    Oleksiewicz MB, Southgate J, Iversen L, Egerod FL. Rat urinary bladder carcinogenesis by dual-acting PPARalpha + gamma agonists. PPAR Res. 2008;2008:103167.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, Wanibuchi H, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci. 2010;113:349–57.PubMedCrossRefGoogle Scholar
  22. 22.
    Varley CL, Southgate J. Effects of PPAR agonists on proliferation and differentiation in human urothelium. Exp Toxicol Pathol. 2008;60:435–41.PubMedCrossRefGoogle Scholar
  23. 23.
    Hardisty JF, Anderson DC, Brodie S, Cline JM, Hahn FF, Kolenda-Roberts H, et al. Histopathology of the urinary bladders of cynomolgus monkeys treated with PPAR agonists. Toxicol Pathol. 2008;36:769–76.PubMedCrossRefGoogle Scholar
  24. 24.
    Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer. 2008;123:2254–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV, et al. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol. 1998;153:349–54.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Sato K, Awasaki Y, Kandori H, Tanakamaru ZY, Nagai H, Baron D, et al. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol. 2011;251:234–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Yang X, Chan JC. Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer. Diabetes Care. 2011;34:e136–7.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Shiyao He
    • 1
  • Yu-hong Tang
    • 2
  • Guobin Zhao
    • 3
  • Xiaolong Yang
    • 4
  • Dehou Wang
    • 4
  • Ye Zhang
    • 4
  1. 1.Department of UrologyWu Qing District People’s HospitalTianjinChina
  2. 2.College of Laboratory MedicineHebei North UniversityZhangjiakouChina
  3. 3.Department of UrologyThe First Affiliated Hospital of Hebei North UniversityZhangjiakouChina
  4. 4.Department of UrologyAffiliated Hospital of Yan’an UniversityYananChina

Personalised recommendations